Meeting
2023 ASCO Annual Meeting
Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
Authors
David D. Tran
Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angleles, CA
David D. Tran , Ashley Parham Ghiaseddin , Dongjiang D. Chen , Son B Le
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03405792
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2024)
DOI
10.1200/JCO.2023.41.16_suppl.2024
Abstract #
2024
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Donna Molaie
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2018 ASCO Annual Meeting
Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.
First Author: Manmeet Singh Ahluwalia
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis